Evercyte to highlight immortalized cell potential in OOAC technology at SelectBIO Europe 2024 Congress

Innovative biotech manufacturer Evercyte will be a prominent presence as an exhibitor and scientific contributor at the upcoming SelectBIO Congress Europe in Rotterdam.

The Evercyte stand at Booth E4 in the Exhibition Zone at the Hilton Rotterdam will highlight its recent moves into OOAC technology, developing a wide range of immortalized cells that can be embedded in human organ-representative microenvironments using microfluidics technology, in partnership with industry Nortis and TissUse.

By combining its extensive range of human telomerized cells with this emerging technology, Evercyte is promoting animal-free drug screening that is also more predictable, patient-relevant, faster and cheaper.

Pre-clinical in-vitro tests

Evercyte co-founder and Chief Scientific Officer Dr. Regina Grillari will also contribute to the Day Two ‘Technology Trends and Advances’ session as part of the Organoids and Spheroids Europe Conference Track.  Her presentation ‘Human Telomerized Cell Cultures to Establish Relevant and Standardizable Pre-Clinical in vitro Test Systems’ will show how the combination of immortalized cell lines and microfluidics can make OOAC technology a significantly more powerful tool to mimic physiological conditions and study organ function. (Tuesday, June 25, 1100 hrs.)

Dr. Grillari will explain current limitations of OOAC due to restricted choice of cell source, with primary cells often exhibiting donor-to-donor variability and limited lifespan, posing challenges in experimental consistency, scalability and long-term studies.

Lifting barriers

Her presentation will show how immortalized cell lines can circumvent these limitations by offering indefinite proliferation potential while maintaining stable genetic and phenotypic characteristics over prolonged culture period providing a reliable platform for embedding into microfluidic OOAC devices.

Evercyte’s portfolio offers a variety of immortalized cell lines derived from various tissues, that show morphology, phenotype, and functions of the corresponding primary cells. Its telomerized cell lines have been seamlessly integrated with microfluidic technology and maintained expression of the essential markers and morphology culminating in the creation of single and multi-organ chips. The adoption of immortalized cells into OOAC models faithfully replicated critical in vivo elements, presenting a robust platform for studying cellular responses, toxicity, and biomarkers, suitable for preclinical research.

Immortalized cell lines

Evercyte will also be represented in Rotterdam by its Head of Science & Business Communication, Dr. Giulia Corso.

Dr. Corso commented: “We will also use this exciting conference as an opportunity to highlight our portfolio of immortalized cells, that can be used for different applications, such as producing scalable clinical-grade extracellular vesicles (EVs), establishing complex in vitro models, simulating single or multi-organ systems, and constructing living tissue models with bioprinting.”

“I invite anyone interested in learning more about Evercyte products and services during the conference, or who wishes to schedule a personal meeting, to contact me at giulia.corso(at)evercyte.com,” Dr. Corso added.

About Evercyte GmbH

Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel cell lines for production of extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.

The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalogue of readily available cell lines for the production of extracellular vesicles from mesenchymal stromal cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.

By providing native extracellular vesicles from mesenchymal stromal cells Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs e.g. tissue targeting and targeted drug delivery.

Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in vitro bioassays as well as relevant cell models and cell factories.

Learn more at: http://www.evercyte.com

About SelectBIO Europe 2024

The SelectBIO Congress brings together researchers and industry participants from both academia and industry focusing on technology and innovation in different fields.

Founded in 2008, the congress has expanded to incorporate four co-located and concurrent conference tracks that include Lab-on-a-Chip & Microfluidics 2024, Point-of-Care, Biosensors & Mobile Diagnostics Europe 2024, Organoids and Spheroids Europe Europe 2024, and Circulating Biomarkers and Extracellular Vesicles Europe 2024.

The 2024 SelectBIO Congress will again be a two-day event opening June 24 at the Hilton Rotterdam, in The Netherlands.

The conferences will reflect extensive international perspectives, with speakers, poster presentations, sponsors, and exhibitors drawn from Europe, North America, and Asia/Pacific. The co-located exhibition will cover latest technological advances and associated products and services from leading solution providers from around the world.

Further information about the event at: https://selectbiosciences.com/conferences.aspx?country=Europe

Resources

Click on Human Telomerized Cell Cultures to Establish Relevant and Standardizable Pre-Clinical in vitro Test Systems for abstract of presentation.
Click on Evercyte immortalized cell lines compatible with OOAC organ on chip technology to learn more.
Click on Evercyte products for further information.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.